1	5	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Microparticles	_	_	NNS	_	_	_	_	_
2	as	_	_	IN	_	_	_	_	_
3	an	_	_	DT	_	_	_	_	_
4	Indicator	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	Disease	_	_	NN	_	_	_	_	_
7	Activity	_	_	NN	_	_	_	_	_


1	Microparticles	_	_	NNS	_	_	_	_	_
2	have	_	_	VBP	_	_	_	_	_
3	been	_	_	VBN	_	_	_	_	_
4	attracting	_	_	VBG	_	_	_	_	_
5	increasing	_	_	VBG	_	_	_	_	_
6	attention	_	_	NN	_	_	_	_	_
7	as	_	_	IN	_	_	_	_	_
8	potential	_	_	JJ	_	_	_	_	_
9	indicators	_	_	NNS	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	eukaryotic	_	_	JJ	_	_	_	_	_
12	cell	_	_	NN	_	_	_	_	_
13	activation	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	They	_	_	PRP	_	_	_	_	_
2	could	_	_	MD	_	_	_	_	_
3	provide	_	_	VB	_	_	_	_	_
4	valuable	_	_	JJ	_	_	_	_	_
5	information	_	_	NN	_	_	_	_	_
6	on	_	_	IN	_	_	_	_	_
7	inflammatory	_	_	JJ	_	_	_	_	_
8	processes	_	_	NNS	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	progress	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	disease	_	_	NN	_	_	_	_	_
13	activity	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	response	_	_	NN	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	treatment	_	_	NN	_	_	_	_	_
20	as	_	_	RB	_	_	_	_	_
21	well	_	_	RB	_	_	_	_	_
22	as	_	_	IN	_	_	_	_	_
23	prognosis	_	_	NN	_	_	_	_	_
24	as	_	_	IN	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	disease	_	_	NN	_	_	_	_	_
27	assessment	_	_	NN	_	_	_	_	_
28	indicator	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Hsu	_	_	NNP	_	_	_	_	_
2	et	_	_	NNP	_	_	_	_	_
3	al.	_	_	FW	_	_	_	_	_
4	demonstrated	_	_	VBD	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	release	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	MPs	_	_	NNS	_	_	_	_	_
9	from	_	_	IN	_	_	_	_	_
10	platelets	_	_	NNS	_	_	_	_	_
11	activated	_	_	VBN	_	_	_	_	_
12	with	_	_	IN	_	_	_	_	_
13	collagen	_	_	NN	_	_	_	_	_
14	decreased	_	_	VBN	_	_	_	_	_
15	considerably	_	_	RB	_	_	_	_	_
16	after	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	activity	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	kinase	_	_	NN	_	_	_	_	_
21	BTK	_	_	NN	_	_	_	_	_
22	was	_	_	VBD	_	_	_	_	_
23	inhibited	_	_	VBN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Reduction	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	PMPs	_	_	NN	_	_	_	_	_
4	numbers	_	_	NNS	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	other	_	_	JJ	_	_	_	_	_
7	studies	_	_	NNS	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	BTK	_	_	NNP	_	_	_	_	_
10	inhibitor	_	_	NN	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	platelet	_	_	NN	_	_	_	_	_
13	cultures	_	_	NNS	_	_	_	_	_
14	was	_	_	VBD	_	_	_	_	_
15	associated	_	_	VBN	_	_	_	_	_
16	with	_	_	IN	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	decrease	_	_	NN	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	production	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	release	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	inflammatory	_	_	JJ	_	_	_	_	_
26	cytokines	_	_	NNS	_	_	_	_	_
27	IL-6	_	_	NNP	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	IL-8	_	_	NNP	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	considerable	_	_	JJ	_	_	_	_	_
3	increase	_	_	NN	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	number	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	platelet	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	monocyte	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	lymphocyte-derived	_	_	JJ	_	_	_	_	_
14	microparticles	_	_	NNS	_	_	_	_	_
15	(	_	_	-LRB-	_	_	_	_	_
16	CD3	_	_	NNP	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	CD19	_	_	NN	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	has	_	_	VBZ	_	_	_	_	_
21	been	_	_	VBN	_	_	_	_	_
22	observed	_	_	VBN	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	RA	_	_	NNP	_	_	_	_	_
25	patients	_	_	NNS	_	_	_	_	_
26	with	_	_	IN	_	_	_	_	_
27	high	_	_	JJ	_	_	_	_	_
28	disease	_	_	NN	_	_	_	_	_
29	activity	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_
31	Rodrigez-Cario	_	_	NNP	_	_	_	_	_
32	et	_	_	FW	_	_	_	_	_
33	al.	_	_	FW	_	_	_	_	_
34	examined	_	_	VBD	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	amount	_	_	NN	_	_	_	_	_
37	of	_	_	IN	_	_	_	_	_
38	circulating	_	_	VBG	_	_	_	_	_
39	microparticles	_	_	NNS	_	_	_	_	_
40	and	_	_	CC	_	_	_	_	_
41	their	_	_	PRP$	_	_	_	_	_
42	origin	_	_	NN	_	_	_	_	_
43	in	_	_	IN	_	_	_	_	_
44	114	_	_	CD	_	_	_	_	_
45	RA	_	_	NN	_	_	_	_	_
46	patients	_	_	NNS	_	_	_	_	_
47	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	total	_	_	JJ	_	_	_	_	_
3	number	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	MPs	_	_	NNS	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	platelet	_	_	NN	_	_	_	_	_
8	poor	_	_	JJ	_	_	_	_	_
9	plasma	_	_	NN	_	_	_	_	_
10	was	_	_	VBD	_	_	_	_	_
11	much	_	_	RB	_	_	_	_	_
12	higher	_	_	JJR	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	individuals	_	_	NNS	_	_	_	_	_
15	with	_	_	IN	_	_	_	_	_
16	arthritis	_	_	NN	_	_	_	_	_
17	compared	_	_	VBN	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	group	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	healthy	_	_	JJ	_	_	_	_	_
23	individuals	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	occurrence	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	different	_	_	JJ	_	_	_	_	_
5	MPs	_	_	NNS	_	_	_	_	_
6	subtypes	_	_	NNS	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	this	_	_	DT	_	_	_	_	_
9	study	_	_	NN	_	_	_	_	_
10	differed	_	_	VBD	_	_	_	_	_
11	considerably	_	_	RB	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	RA	_	_	NNP	_	_	_	_	_
15	group	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	was	_	_	VBD	_	_	_	_	_
18	associated	_	_	VBN	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	clinical	_	_	JJ	_	_	_	_	_
22	course	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	joint	_	_	JJ	_	_	_	_	_
25	inflammation	_	_	NN	_	_	_	_	_
26	:	_	_	:	_	_	_	_	_
27	The	_	_	DT	_	_	_	_	_
28	amount	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	endothelial	_	_	JJ	_	_	_	_	_
31	MPs	_	_	NNS	_	_	_	_	_
32	was	_	_	VBD	_	_	_	_	_
33	associated	_	_	VBN	_	_	_	_	_
34	with	_	_	IN	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	disease	_	_	NN	_	_	_	_	_
37	duration	_	_	NN	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	the	_	_	DT	_	_	_	_	_
40	amount	_	_	NN	_	_	_	_	_
41	of	_	_	IN	_	_	_	_	_
42	granulocyte	_	_	NN	_	_	_	_	_
43	MPs	_	_	NNS	_	_	_	_	_
44	was	_	_	VBD	_	_	_	_	_
45	associated	_	_	VBN	_	_	_	_	_
46	with	_	_	IN	_	_	_	_	_
47	the	_	_	DT	_	_	_	_	_
48	disease	_	_	NN	_	_	_	_	_
49	activity	_	_	NN	_	_	_	_	_
50	as	_	_	IN	_	_	_	_	_
51	assessed	_	_	VBN	_	_	_	_	_
52	by	_	_	IN	_	_	_	_	_
53	DAS28	_	_	NNP	_	_	_	_	_
54	,	_	_	,	_	_	_	_	_
55	whereas	_	_	IN	_	_	_	_	_
56	the	_	_	DT	_	_	_	_	_
57	amount	_	_	NN	_	_	_	_	_
58	of	_	_	IN	_	_	_	_	_
59	monocyte-derived	_	_	JJ	_	_	_	_	_
60	MPs	_	_	NNS	_	_	_	_	_
61	was	_	_	VBD	_	_	_	_	_
62	associated	_	_	VBN	_	_	_	_	_
63	with	_	_	IN	_	_	_	_	_
64	the	_	_	DT	_	_	_	_	_
65	presence	_	_	NN	_	_	_	_	_
66	of	_	_	IN	_	_	_	_	_
67	the	_	_	DT	_	_	_	_	_
68	rheumatoid	_	_	JJ	_	_	_	_	_
69	factor	_	_	NN	_	_	_	_	_
70	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	amount	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	MPs	_	_	NNS	_	_	_	_	_
5	was	_	_	VBD	_	_	_	_	_
6	also	_	_	RB	_	_	_	_	_
7	associated	_	_	VBN	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	presence	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	traditional	_	_	JJ	_	_	_	_	_
13	cardiovascular	_	_	JJ	_	_	_	_	_
14	risk	_	_	NN	_	_	_	_	_
15	factors	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	findings	_	_	NNS	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	Cloutier	_	_	NNP	_	_	_	_	_
5	et	_	_	FW	_	_	_	_	_
6	al.	_	_	FW	_	_	_	_	_
7	could	_	_	MD	_	_	_	_	_
8	indicate	_	_	VB	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	possibility	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	using	_	_	VBG	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	studies	_	_	NNS	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	circulating	_	_	VBG	_	_	_	_	_
17	mpICs	_	_	NNS	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	assess	_	_	VB	_	_	_	_	_
20	RA	_	_	NN	_	_	_	_	_
21	activity	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	different	_	_	JJ	_	_	_	_	_
4	conclusions	_	_	NNS	_	_	_	_	_
5	were	_	_	VBD	_	_	_	_	_
6	presented	_	_	VBN	_	_	_	_	_
7	by	_	_	IN	_	_	_	_	_
8	van	_	_	NNP	_	_	_	_	_
9	Eijk	_	_	NNP	_	_	_	_	_
10	et	_	_	FW	_	_	_	_	_
11	al.	_	_	FW	_	_	_	_	_
12	based	_	_	VBN	_	_	_	_	_
13	on	_	_	IN	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	study	_	_	NN	_	_	_	_	_
16	with	_	_	IN	_	_	_	_	_
17	24	_	_	CD	_	_	_	_	_
18	patients	_	_	NNS	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	an	_	_	DT	_	_	_	_	_
21	early	_	_	JJ	_	_	_	_	_
22	form	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	RA	_	_	NNP	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	disease	_	_	NN	_	_	_	_	_
3	activity	_	_	NN	_	_	_	_	_
4	was	_	_	VBD	_	_	_	_	_
5	assessed	_	_	VBN	_	_	_	_	_
6	based	_	_	VBN	_	_	_	_	_
7	on	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	ESR	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	C-reactive	_	_	JJ	_	_	_	_	_
12	protein	_	_	NN	_	_	_	_	_
13	(	_	_	-LRB-	_	_	_	_	_
14	CRP	_	_	NN	_	_	_	_	_
15	)	_	_	-RRB-	_	_	_	_	_
16	level	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	DAS28	_	_	NNP	_	_	_	_	_
20	score	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	level	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	serum	_	_	NN	_	_	_	_	_
7	amyloid-P	_	_	NN	_	_	_	_	_
8	(	_	_	-LRB-	_	_	_	_	_
9	SAP	_	_	NNP	_	_	_	_	_
10	)	_	_	-RRB-	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	amount	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	circulating	_	_	VBG	_	_	_	_	_
16	MPs	_	_	NNPS	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	MPs	_	_	NNPS	_	_	_	_	_
19	presenting	_	_	VBG	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	C1q	_	_	NNP	_	_	_	_	_
22	complement	_	_	NN	_	_	_	_	_
23	component	_	_	NN	_	_	_	_	_
24	was	_	_	VBD	_	_	_	_	_
25	determined	_	_	VBN	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	patients	_	_	NNS	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Nine	_	_	CD	_	_	_	_	_
2	patients	_	_	NNS	_	_	_	_	_
3	were	_	_	VBD	_	_	_	_	_
4	reassessed	_	_	VBN	_	_	_	_	_
5	after	_	_	IN	_	_	_	_	_
6	an	_	_	DT	_	_	_	_	_
7	eight-week	_	_	JJ	_	_	_	_	_
8	intensive	_	_	JJ	_	_	_	_	_
9	treatment	_	_	NN	_	_	_	_	_
10	according	_	_	VBG	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	COBRA	_	_	NNP	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	COmBination	_	_	NNP	_	_	_	_	_
16	therapy	_	_	NN	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	Rheumatoid	_	_	NNP	_	_	_	_	_
19	Arthritis	_	_	NNP	_	_	_	_	_
20	)	_	_	-RRB-	_	_	_	_	_
21	regimen	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	which	_	_	WDT	_	_	_	_	_
24	included	_	_	VBD	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	combined	_	_	VBN	_	_	_	_	_
27	treatment	_	_	NN	_	_	_	_	_
28	with	_	_	IN	_	_	_	_	_
29	methotrexate	_	_	NN	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	sulfasalazine	_	_	NN	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	and	_	_	CC	_	_	_	_	_
34	prednisolone	_	_	NN	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	As	_	_	IN	_	_	_	_	_
2	expected	_	_	VBN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	ESR	_	_	NNP	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	CRP	_	_	NNP	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	DAS28	_	_	NNP	_	_	_	_	_
10	improved	_	_	VBD	_	_	_	_	_
11	as	_	_	IN	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	result	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	treatment	_	_	NN	_	_	_	_	_
17	;	_	_	:	_	_	_	_	_
18	however	_	_	RB	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	contrary	_	_	VBP	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	expectations	_	_	NNS	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	neither	_	_	CC	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	amount	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	circulating	_	_	VBG	_	_	_	_	_
29	MPs	_	_	NNS	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	nor	_	_	CC	_	_	_	_	_
32	MPs	_	_	NNS	_	_	_	_	_
33	with	_	_	IN	_	_	_	_	_
34	the	_	_	DT	_	_	_	_	_
35	attached	_	_	VBN	_	_	_	_	_
36	C1q	_	_	NNP	_	_	_	_	_
37	component	_	_	NN	_	_	_	_	_
38	decreased	_	_	VBN	_	_	_	_	_
39	,	_	_	,	_	_	_	_	_
40	which	_	_	WDT	_	_	_	_	_
41	suggests	_	_	VBZ	_	_	_	_	_
42	the	_	_	DT	_	_	_	_	_
43	absence	_	_	NN	_	_	_	_	_
44	of	_	_	IN	_	_	_	_	_
45	any	_	_	DT	_	_	_	_	_
46	connection	_	_	NN	_	_	_	_	_
47	between	_	_	IN	_	_	_	_	_
48	the	_	_	DT	_	_	_	_	_
49	activity	_	_	NN	_	_	_	_	_
50	of	_	_	IN	_	_	_	_	_
51	inflammation	_	_	NN	_	_	_	_	_
52	and	_	_	CC	_	_	_	_	_
53	MPs	_	_	NNP	_	_	_	_	_
54	release	_	_	NN	_	_	_	_	_
55	and	_	_	CC	_	_	_	_	_
56	mpIC	_	_	NN	_	_	_	_	_
57	production	_	_	NN	_	_	_	_	_
58	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	a	_	_	DT	_	_	_	_	_
3	recent	_	_	JJ	_	_	_	_	_
4	paper	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	Chen	_	_	NNP	_	_	_	_	_
7	demonstrated	_	_	VBD	_	_	_	_	_
8	that	_	_	IN	_	_	_	_	_
9	inhibition	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	PMPs	_	_	NNP	_	_	_	_	_
12	formation	_	_	NN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	an	_	_	DT	_	_	_	_	_
15	animal	_	_	NN	_	_	_	_	_
16	model	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	CIA	_	_	NNP	_	_	_	_	_
19	(	_	_	-LRB-	_	_	_	_	_
20	collagen-induced	_	_	JJ	_	_	_	_	_
21	arthritis	_	_	NN	_	_	_	_	_
22	)	_	_	-RRB-	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	reduction	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	circulating	_	_	VBG	_	_	_	_	_
27	PMPs	_	_	NNP	_	_	_	_	_
28	was	_	_	VBD	_	_	_	_	_
29	associated	_	_	VBN	_	_	_	_	_
30	with	_	_	IN	_	_	_	_	_
31	a	_	_	DT	_	_	_	_	_
32	clinical	_	_	JJ	_	_	_	_	_
33	decrease	_	_	NN	_	_	_	_	_
34	in	_	_	IN	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	disease	_	_	NN	_	_	_	_	_
37	activity	_	_	NN	_	_	_	_	_
38	assessed	_	_	VBN	_	_	_	_	_
39	as	_	_	IN	_	_	_	_	_
40	joint	_	_	JJ	_	_	_	_	_
41	swelling	_	_	NN	_	_	_	_	_
42	and	_	_	CC	_	_	_	_	_
43	stiffness	_	_	NN	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_

